July 2, 2021 7:56am

I’ve already mentally bolted for the long weekend and upcoming week

Pre-open indications: 2 BUYs: RARE, CRSP; 2 Sells into Strength – Profit: NTLA, EDIT; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are UP +0.04% (+14 points), S&P futures are UP +0.10% (+5 point) and NASDAQ futures are UP +0.29% (+42 points)

 

Stock futures were barely up in early premarket trade as investors looked ahead to the Labor Department’s all-important monthly jobs report,

European markets were slightly higher,

Asia-Pacific stocks were mixed as MSCI’s broadest index of Asia-Pacific shares outside Japan slipped 0.95%.

 

Data Docket: The economy added 850,000 jobs last month, according to the Bureau of Labor Statistics. Economists were expecting an addition of 706,000. The print topped the 559,000 jobs created in May. The unemployment rate did come in at 5.9%, higher than expected.

  • “The data for recent months suggest that the rising demand for labor associated with the recovery from the pandemic may have put upward pressure on wages,” the Bureau of Labor Statistics said in its report.

 

Henry’omics:

Futures contracts tied to the major U.S. stock indexes seem flat on Friday as the long holiday weekend has already started.

A relevant quote, “For the first time in over two years, the upcoming jobs report may make the Fed get more aggressive about reducing accommodation, and as such the biggest risk for tomorrow’s report is that it’s ‘Too Hot,’” The Sevens Report founder Tom Essaye wrote.

 

Thursday’s evening’s recap: “cell and gene therapy sector bounces after Wednesday’s slight slippage. Yet, a profit-taking session with news from Mesoblast (MESO) with a pre-open of +$1.12 which only closed +$0.06 – oh, the strippage but, its till closed positive.” … https://www.regmedinvestors.com/articles/11982

  • The Nasdaq closed UP +18.42 points (+0.13%);
  • The IBB closed up +0.89% and XBI closed up +2.28%;
  • Sector volume was LOW with 5 of the 25-upside having higher than the 3-month average volume with LOW volume of 3 of 8-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -0.35 points or -2.21% at 15.48;
  • Thursday’s percentage (%) of the 25-upside were +0.14% (ALNY) to +8.64% (FATE) while the 8-downside ranges from -0.21% (EDIT) to -3.24% (CRSP);

Q3/21: 1 positive close

Q2/21:

·         June: 15 positive and 8 negative closes

·         May:  8 positive, 12 negative closes and 1 holiday

·         April: 11 negative and 10 positive closes

Q1/21:

·         March: 10 positive, 12 negative and 1 neutral closes

·         February: 9 positive, 10 negative closes and 1 holiday

·         January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – Could the share price stay up if it wasn’t “pumped”?

Biostage (BSTG) closed up +$0.095 to $1.35 with 408 shares traded following Wednesday’s  -$0.005 to $1.25 with 3,241 shares traded, Tuesday’s +$0.03 to $1.26 with 1,860 shares traded, Monday’s -$0.02 to $1.23 with 1,177 shares traded and last Friday’s -$0.10 to $1.25 with 1,00 shares traded.

Question#1: WHAT role is DST Capital “playing” in these on-going “volume-pumping” pricing “moves” – to keep the company from being de-listed?

Question#2: Does anyone see the patterns that I see?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

BUY:

Ultragenyx (RARE) closed down -$1.24 to $94.11 with a positive +$2.29 or +2.43% aftermarket indication.

CRISPR Therapeutics (CRSP) closed down -$5.25 to $156.64 after Wednesday’s +$11.40 to $161.89, Tuesday’s -$1.14 to $150.49, Monday’s +$9.111 to $151.63 and last Friday’s +$4.76 to $142.52, with a positive +$0.16 or +0.10% pre-market indication.

 

Maintaining SELL into Strength:

Intellia Therapeutics (NTLA) closed up +$9.74 to $171.65 after Wednesday’s +$10.30 to $161.91, Tuesday’s +$18.18 to $151.61, Monday’s +$44.60 to $133.43 and last Friday’s +$1.99 to $88.83 with a positive +$1.35 or +0.79% pre-market indication after jumping on news and pricing a $600 M offering at $145.00.

Editas Medicine (EDIT) closed down -$0.12 to $56.52 after Wednesday’s +$10.54 to $56.64 after Tuesday’s +$2.11 to $46.10, Monday’s +$2.11 to $43.99, Friday’s +$1.01 to $41.88 and last Thursday’s +$3.05 to $40.87, and has a negative -$1.02 or -1.80% pre-market indication.

 

 

The BOTTOM LINE: In my role as a research analyst and journalist, many times I scratch my head over how to cover volatile cell and gene therapy equities – it’s the INDICATIONS that focus my “leanings”.

I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have